C12N15/01

Disease resistant onion plants

The present invention relates to a mutant onion (Allium cepa) plant, which is resistant to a pathogen of viral, bacterial, fungal or oomycete origin. The mutant onion plant has a reduced level, reduced activity or complete absence of AcDMR6 protein as compared to a wild type onion plant.

INCORPORATION OF UNNATURAL AMINO ACIDS INTO PROTEINS USING BASE EDITING

Provided herein are systems, compositions, and methods for the incorporation of unnatural amino acids into proteins via nonsense suppression or rare codon suppression. Nonsense codons and rare codons may be introduced into the coding sequence of a protein of interest using a CRISPR/Cas9-based nucleobase editor described herein. The nucleobase editors are able to be programmed by guide nucleotide sequences to edit the target codons in the coding sequence of the protein of interest. Also provided are application enabled by the technology described herein.

Antibiotic sensitive Bacillus strains having antimicrobial effect against E. coli and Clostridium perfringens and having high sporulation capacity

A Bacillus strain characterized by (i): sensitivity for ampicillin, vancomycin, gentamicin, kanamycin, streptomycin, erythromycin, clindamycin, tetracycline and chloramphenicol; (ii) antimicrobial activity against E. coli and Clostridium perfringens; and (iii) a sporulation percentage of at least 80 when measured after 2 days of incubation. The invention further relates to a method for selecting such strains. Many of the identified strains according to the invention are of the species Bacillus amyloliquefaciens. Some of the Bacillus amyloliquefaciens were further identified as Bacillus amyloliquefaciens subsp. amyloliquefaciens whereas others were identified as amyloliquefaciens subsp. plantarum. A Bacillus strain of the invention may be used as a feed additive to animal feed where it has a probiotic effect.

Antibiotic sensitive Bacillus strains having antimicrobial effect against E. coli and Clostridium perfringens and having high sporulation capacity

A Bacillus strain characterized by (i): sensitivity for ampicillin, vancomycin, gentamicin, kanamycin, streptomycin, erythromycin, clindamycin, tetracycline and chloramphenicol; (ii) antimicrobial activity against E. coli and Clostridium perfringens; and (iii) a sporulation percentage of at least 80 when measured after 2 days of incubation. The invention further relates to a method for selecting such strains. Many of the identified strains according to the invention are of the species Bacillus amyloliquefaciens. Some of the Bacillus amyloliquefaciens were further identified as Bacillus amyloliquefaciens subsp. amyloliquefaciens whereas others were identified as amyloliquefaciens subsp. plantarum. A Bacillus strain of the invention may be used as a feed additive to animal feed where it has a probiotic effect.

LONG CHAIN DIBASIC ACID WITH LOW CONTENT OF LONG CHAIN DIBASIC ACID IMPURITY OF SHORTER CARBON-CHAIN AND PREPARATION METHOD THEREOF
20220380816 · 2022-12-01 ·

The present invention relates to a long-chain dibasic acid with low content of long-chain dibasic acid impurity of shorter carbon chain, to the preparation of a long-chain dibasic acid producing strain by directed evolution of POX gene and homologous recombination, and to the production of a long-chain dibasic acid with low content of long-chain dibasic acid impurity of shorter carbon chain by using the strain. The present invention also relates to a strain containing a mutated promoter, wherein, when a long-chain dibasic acid is produced by fermentation of this strain, the content of the acid impurity of shorter carbon chain in the fermentation product is significantly reduced.

Propiconazole resistant mutants of Chlorella Species

The present disclosure relates to propiconazole resistant mutants of Chlorella species having Accession No. CCAP 211/134. The propiconazole resistant mutants of Chlorella species has increased tolerance to propiconazole and has increased tolerance to abiotic stress. The present disclosure further provides a method for preparing the propiconazole resistant mutants of Chlorella species. The propiconazole resistant mutants of Chlorella species can selectively grow in the presence of propiconazole, has increased tolerance to temperature stress, and hence can be used for large scale production of algal biomass.

Propiconazole resistant mutants of Chlorella Species

The present disclosure relates to propiconazole resistant mutants of Chlorella species having Accession No. CCAP 211/134. The propiconazole resistant mutants of Chlorella species has increased tolerance to propiconazole and has increased tolerance to abiotic stress. The present disclosure further provides a method for preparing the propiconazole resistant mutants of Chlorella species. The propiconazole resistant mutants of Chlorella species can selectively grow in the presence of propiconazole, has increased tolerance to temperature stress, and hence can be used for large scale production of algal biomass.

Methods for nucleic acid editing

Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins of Cas9 and nucleic acid editing enzymes or enzyme domains, e.g., deaminase domains, are provided. In some embodiments, methods for targeted nucleic acid editing are provided. In some embodiments, reagents and kits for the generation of targeted nucleic acid editing proteins, e.g., fusion proteins of Cas9 and nucleic acid editing enzymes or domains, are provided.

Methods for nucleic acid editing

Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins of Cas9 and nucleic acid editing enzymes or enzyme domains, e.g., deaminase domains, are provided. In some embodiments, methods for targeted nucleic acid editing are provided. In some embodiments, reagents and kits for the generation of targeted nucleic acid editing proteins, e.g., fusion proteins of Cas9 and nucleic acid editing enzymes or domains, are provided.

RNA-guided human genome engineering

A method of altering a eukaryotic cell is provided including transfecting the eukaryotic cell with a nucleic acid encoding RNA complementary to genomic DNA of the eukaryotic cell, transfecting the eukaryotic cell with a nucleic acid encoding an enzyme that interacts with the RNA and cleaves the genomic DNA in a site specific manner, wherein the cell expresses the RNA and the enzyme, the RNA binds to complementary genomic DNA and the enzyme cleaves the genomic DNA in a site specific manner.